NERATINIB, HKI 272, ..Puma presents positive results from phase II trial of its investigational drug PB272 | New Drug Approvals
Neratinib in Early-Stage Breast Cancer: A Profile of Its Use in the EU | Clinical Drug Investigation
Puma Biotech anti-HER2 breast cancer drug approved in China - BioTuesdays
Neratinib | 99.94%(HPLC) | In Stock | HER2 inhibitor
Neratinib maleate (HKI-272 maleate) | HER2/EGFR Inhibitor | MedChemExpress
Puma Bio FDA Advisory Panel Live Blog - TheStreet
Puma Biotechnology Presents Interim Results of Phase II CONTROL Trial of Neratinib in Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer at the 2019 SABCS | BioSpace
A New Drug on the Horizon for HER2 Breast Cancer Patients | Avise Analytics
Puma Biotechnology Presents Results from the Phase II SUMMIT Trial of Neratinib for ERBB2 (HER2) Mutant, HER2 Non-Amplified, Metastatic Breast Cancer at the 2019 San Antonio Breast Cancer Symposium | Business Wire
Why Puma Biotechnology (PBYI) Stock Is Surging Today - TheStreet
Neratinib for breast cancer – the key is managing gastrointestinal toxicity | Cancer Biology
FDA panel backs Puma's neratinib, clearing path to approval | Fierce Biotech
Buy Nerlynx (neratinib) Online • Price & Costs | Everyone.org
Mechanism of action | NERLYNX® (neratinib) tablets
A New Drug on the Horizon for HER2 Breast Cancer Patients | Avise Analytics
Puma Biotechnology
Antitumour activity of neratinib in patients with HER2-mutant advanced biliary tract cancers | Nature Communications
Puma Biotechnology Presents Interim Results from the Biliary Tract Cancers Cohort of the Phase II SUMMIT “Basket” Trial of Neratinib at ASCO GI | Business Wire
Puma Biotechnology Presents Results from the Phase II SUMMIT Trial of Neratinib for ERBB2 (HER2) Mutant, HER2 Non-Amplified, Metastatic Breast Cancer at the 2019 San Antonio Breast Cancer Symposium | BioSpace
Puma Biotechnology expands deal with Pierre Fabre to include additiona
Puma Biotechnology Presents Final Results from the Biliary Tract Cohort of the Phase 2 SUMMIT 'Basket' Trial of Neratinib at the ASCO 2022 Annual Meeting | Business Wire
pbyi20211231_10k.htm
Puma Biotechnology
